Improve health outcomes by preventing DKA at diagnosis.
Accelerate disease-modifying therapies through the pipeline by increasing the number of people eligible for clinical trials.
Identify people who can benefit from disease-modifying therapies as they become available.
Powering the research and development of new therapies that can slow, halt, or reverse the course of T1D, curing people across the various stages of the disease.
Investing in research and clinical trials aimed at developing and delivering life-changing therapies that insert healthy, insulin-producing beta cells into people with T1D, with minimal or no immunosuppression, keeping them healthy for longer.
People with T1D must have tools, therapies, and interventions to keep them healthy so that when cures come to fruition, they are healthy enough to take advantage of them.